The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia

Abstract Background To understand the implications of switching from paliperidone palmitate 1-monthly (PP1M) to 3-monthly (PP3M) treatment schizophrenia perspective four key stakeholders: patients, physicians, nurses and carers. Methods This was a cross-sectional, retrospective, non-interventional study comprising one-time questionnaire (PINC-Q) for adult patients (aged ?18 years) with (International Classification Diseases; ICD-10) their physician, nurse carer. Questionnaires were developed in association patient carer advocacy groups (GAMIAN EUFAMI) following an advisory board formed psychiatrists nurses. The degree alignment between stakeholders also examined. Results Responses received total 224 evaluable patients. For most (88.4%), responses at least two other stakeholders. Patients moderately ill mild-to-moderate lack insight had PP1M mean (standard deviation [SD]) 23.9 (21.28) months before PP3M (duration [SD] 12.8 [3.72] months). frequently reported reasons switch ‘to live life as normally possible’ ‘patient convenience’. Over 79% within each stakeholder group stated that helped increased activity social involvement, improved frequency quality physician–patient nurse–patient communication decreased perceived stigma. Conclusions results this add increasing body evidence supporting benefits population representative real-world clinical practice.